ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $937,821 | -18.1% | 45,001 | -5.9% | 0.01% | -11.1% |
| Q2 2023 | $1,145,672 | +19.5% | 47,836 | -6.1% | 0.01% | +12.5% |
| Q1 2023 | $958,559 | +267.3% | 50,933 | +373.7% | 0.01% | +300.0% |
| Q1 2022 | $261,000 | +20.8% | 10,753 | +16.6% | 0.00% | +100.0% |
| Q4 2021 | $216,000 | -86.2% | 9,220 | -90.2% | 0.00% | -88.9% |
| Q3 2021 | $1,566,000 | -19.4% | 94,279 | +18.4% | 0.01% | -18.2% |
| Q2 2021 | $1,942,000 | -3.8% | 79,613 | +1.8% | 0.01% | -15.4% |
| Q1 2021 | $2,018,000 | -31.7% | 78,233 | +41.6% | 0.01% | -31.6% |
| Q4 2020 | $2,953,000 | -8.5% | 55,237 | -29.4% | 0.02% | -17.4% |
| Q3 2020 | $3,228,000 | -25.1% | 78,246 | -12.0% | 0.02% | -30.3% |
| Q2 2020 | $4,311,000 | +25.2% | 88,951 | +9.2% | 0.03% | -5.7% |
| Q1 2020 | $3,442,000 | -19.0% | 81,469 | -18.0% | 0.04% | +9.4% |
| Q4 2019 | $4,251,000 | +40.7% | 99,371 | +18.4% | 0.03% | +33.3% |
| Q3 2019 | $3,022,000 | -0.9% | 83,954 | -26.4% | 0.02% | -4.0% |
| Q2 2019 | $3,050,000 | -12.2% | 114,109 | -11.8% | 0.02% | -10.7% |
| Q1 2019 | $3,475,000 | +32.5% | 129,407 | -20.2% | 0.03% | +27.3% |
| Q4 2018 | $2,622,000 | -23.9% | 162,169 | -2.3% | 0.02% | 0.0% |
| Q3 2018 | $3,445,000 | +30.2% | 165,934 | -4.2% | 0.02% | +22.2% |
| Q2 2018 | $2,645,000 | -23.8% | 173,298 | +12.1% | 0.02% | +125.0% |
| Q1 2018 | $3,472,000 | -21.1% | 154,549 | +5.8% | 0.01% | -20.0% |
| Q4 2017 | $4,399,000 | -28.0% | 146,112 | -10.0% | 0.01% | -28.6% |
| Q3 2017 | $6,113,000 | +27.7% | 162,263 | -5.5% | 0.01% | +7.7% |
| Q2 2017 | $4,787,000 | +10.0% | 171,636 | +35.7% | 0.01% | +8.3% |
| Q1 2017 | $4,350,000 | +11.5% | 126,508 | -6.5% | 0.01% | +9.1% |
| Q4 2016 | $3,903,000 | -5.5% | 135,350 | +4.2% | 0.01% | -15.4% |
| Q3 2016 | $4,131,000 | +4.5% | 129,878 | +6.6% | 0.01% | +8.3% |
| Q2 2016 | $3,953,000 | -17.6% | 121,795 | -29.0% | 0.01% | -20.0% |
| Q1 2016 | $4,798,000 | -30.1% | 171,597 | -10.9% | 0.02% | -25.0% |
| Q4 2015 | $6,868,000 | -12.1% | 192,660 | -18.5% | 0.02% | -16.7% |
| Q3 2015 | $7,813,000 | -31.5% | 236,261 | -13.2% | 0.02% | -14.3% |
| Q2 2015 | $11,399,000 | +34.1% | 272,175 | +4.3% | 0.03% | +40.0% |
| Q1 2015 | $8,503,000 | +20.2% | 260,914 | +17.1% | 0.02% | +11.1% |
| Q4 2014 | $7,074,000 | +48.7% | 222,812 | +15.9% | 0.02% | +63.6% |
| Q3 2014 | $4,758,000 | +7.0% | 192,180 | -2.3% | 0.01% | 0.0% |
| Q2 2014 | $4,445,000 | -18.2% | 196,756 | -11.9% | 0.01% | -26.7% |
| Q1 2014 | $5,431,000 | +10.7% | 223,229 | +13.7% | 0.02% | 0.0% |
| Q4 2013 | $4,908,000 | -5.5% | 196,405 | +3.9% | 0.02% | -21.1% |
| Q3 2013 | $5,193,000 | -3.3% | 189,058 | -36.1% | 0.02% | -17.4% |
| Q2 2013 | $5,370,000 | – | 295,872 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |